{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:10:57Z","timestamp":1788876657345,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Ventilator-associated pneumonia (VAP) is a common and serious nosocomial infection in mechanically ventilated preterm infants and is increasingly caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative organisms. Tigecycline, a glycylcycline with broad activity against many such pathogens, is not approved below 18 years of age and carries a boxed warning for excess mortality that is most pronounced in hospital-acquired and ventilator-associated pneumonia. Its role, if any, in preterm infants with VAP is undefined. Objectives: To systematically identify and appraise all human evidence on the efficacy (clinical cure, microbiological eradication, survival) and safety (adverse events, mortality) of tigecycline used to treat VAP or nosocomial pneumonia during mechanical ventilation in preterm infants and neonates. Methods: A PRISMA 2020 structured search of PubMed\/MEDLINE, Cochrane CENTRAL, Scopus, trial registries, regulatory documents, Google Scholar and reference lists was designed without language or date restrictions. Eligible reports described tigecycline treatment of pneumonia\/VAP in neonates or young infants; pediatric case series and syntheses were retained as contextual evidence. Because only case reports and small non-comparative series were anticipated, a narrative synthesis was pre-specified; JBI tools and GRADE were planned for appraisal and certainty. Results: No randomized controlled trial, controlled observational study, or study dedicated to tigecycline for VAP in preterm infants was identified. Direct evidence meeting the full eligibility criteria (preterm neonate, VAP specifically, separately extractable outcomes) was limited to two case reports of extremely preterm neonates with VAP successfully weaned after tigecycline-based salvage combination therapy. Six further neonatal\/young-infant reports initially considered were, on full-text re-review, reclassified as contextual (not index) evidence because they described non-VAP infections (sepsis, or CNS infections such as ventriculitis\/meningitis), non-preterm ages, or mixed-infection series without separable VAP data. Reported outcomes were generally favorable in published cases but are subject to severe selection and publication bias; thrombocytopenia, hypofibrinogenemia and hepatic enzyme elevation were the principal adverse signals, against a class-level mortality signal concentrated in VAP. Quantitative pooling was not appropriate. The overall certainty of evidence was very low. Conclusions: There is no direct, credible efficacy or safety evidence supporting tigecycline for VAP in preterm infants. Available data neither establish benefit nor exclude harm. Based on this very-low-certainty evidence and on regulatory\/class-level safety data rather than on demonstrated efficacy, tigecycline warrants consideration only as a last-resort, combination salvage option for culture-confirmed pan- or extensively drug-resistant pathogens when no safer alternative exists, with intensive monitoring and, ideally, within a registry or trial. Adequately designed neonatal pharmacokinetic and comparative safety studies are urgently needed. Registration: PROSPERO CRD420261450972 (registered 14 July 2026).<\/jats:p>","DOI":"10.3390\/life16091502","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:46:33Z","timestamp":1788875193000},"page":"1502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence for the Efficacy and Safety of Tigecycline for the Treatment of Ventilator-Associated Pneumonia in Preterm Infants: A Systematic Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Gorana","family":"Nedin Rankovi\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacology with Toxicology, Faculty of Medicine, University of Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Krtini\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Oncology, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Nikoli\u0107","sequence":"additional","affiliation":[{"name":"Department of Surgery and Anesthesiology with Reanimatology, Faculty of Medicine, University of Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Clinic for Anesthesia and Intensive Care, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1369-6276","authenticated-orcid":false,"given":"Nada","family":"Pej\u010di\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Anesthesia and Intensive Care, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2605-1562","authenticated-orcid":false,"given":"Nemanja","family":"Dimi\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Anesthesiology, Reanimatology and Intensive Care, University Clinical Hospital Centre \u201cDr Dragi\u0161a Mi\u0161ovi\u0107-Dedinje\u201d, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-5123","authenticated-orcid":false,"given":"Nikola","family":"Milenkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Epidemiology, Faculty of Medicine, University of Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Clinic for Infectious Diseases, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-990X","authenticated-orcid":false,"given":"Iva","family":"Bini\u0107","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, University of Ni\u0161, 18000 Ni\u0161, Serbia"},{"name":"Clinic for Psychiatry, University Clinical Center Ni\u0161, 18000 Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-7669","authenticated-orcid":false,"given":"Branislava","family":"Rankovi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2217\/fmb-2018-0108","article-title":"Ventilator-associated pneumonia in neonates and children: A systematic analysis of diagnostic methods and prevention","volume":"13","author":"Iosifidis","year":"2018","journal-title":"Future Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rangelova, V., Kevorkyan, A., Raycheva, R., and Krasteva, M. (2024). Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit\u2014Incidence and Strategies for Prevention. Diagnostics, 14.","DOI":"10.3390\/diagnostics14030240"},{"key":"ref_3","first-page":"1559","article-title":"Early molecular markers of ventilator-associated pneumonia in bronchoalveolar lavage in preterm infants","volume":"93","author":"Aguar","year":"2022","journal-title":"Pediatr. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/INF.0000000000002339","article-title":"Safety and efficacy of tigecycline to treat multidrug-resistant infections in pediatrics: An evidence synthesis","volume":"38","author":"Sharland","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3855\/jidc.20361","article-title":"Tigecycline therapy for multidrug-resistant bacteria: Is it the right choice for pediatric patients?","volume":"19","author":"Avcu","year":"2025","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_6","unstructured":"(2026, July 16). TYGACIL (Tigecycline) for Injection: US Prescribing Information. Pfizer\/Wyeth Pharmaceuticals; Revised 2025, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021821s056lbl.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","article-title":"All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials","volume":"41","author":"McGovern","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14787210.2017.1318064","article-title":"Use of tigecycline in pediatric clinical practice","volume":"15","author":"Mastrolia","year":"2017","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_9","first-page":"149","article-title":"Use of tigecycline in neonates with extensively drug-resistant organisms infections in the neonatal units of Queen Sirikit National Institute of Child Health","volume":"45","author":"Kanjanapattanakul","year":"2020","journal-title":"J. Dep. Med. Serv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0038-1675582","article-title":"Tigecycline use in neonates: 5-year experience of a tertiary center","volume":"14","year":"2019","journal-title":"J. Pediatr. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Moola, S., Munn, Z., Tufanaru, C., Aromataris, E., Sears, K., Sfetcu, R., Judith Currie, M., Lisy, K., Qureshi, R., and Mattis, P. (2020). Systematic reviews of etiology and risk (JBI critical appraisal tools for case reports and case series). JBI Manual for Evidence Synthesis, JBI.","DOI":"10.46658\/JBIRM-17-06"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1097\/INF.0000000000002348","article-title":"First Case Report of Intraventricular Tigecycline in a Neonate with Extensively Drug-Resistant Acinetobacter baumannii Ventriculitis","volume":"38","author":"Pratheep","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13099-018-0253-x","article-title":"Tigecycline application in a 3-month-old infant with multiple drug-resistant Klebsiella pneumoniae: A case report","volume":"10","author":"Peng","year":"2018","journal-title":"Gut Pathog."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s42399-020-00395-w","article-title":"Tigecycline therapy for multidrug-resistant Pseudomonas aeruginosa sepsis associated with multi-organ failure in an infant with persistent arterial duct: Case report","volume":"2","author":"Krasnanova","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/jmedsci.jmedsci_221_24","article-title":"Managing drug-resistant Acinetobacter baumannii infection in premature infants","volume":"45","author":"Zeng","year":"2025","journal-title":"J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, H., and Tan, Y. (2026). Combination of aztreonam, colistin and tigecycline in the treatment of neonatal carbapenemase-producing Enterobacteriaceae infection: A case report. BMC Pediatr., 26.","DOI":"10.1186\/s12887-026-06511-4"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/CIDS.CIDS_58_23","article-title":"Tigecycline as salvage therapy in a neonate with multidrug-resistant Klebsiella pneumoniae meningitis and ventriculitis: Case report and literature review","volume":"2","author":"Arora","year":"2024","journal-title":"J. Clin. Infect. Dis. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.08.007","article-title":"Tigecycline salvage therapy for critically ill children with multidrug-resistant\/extensively drug-resistant infections after surgery","volume":"75","author":"Song","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s11096-018-0690-0","article-title":"Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies","volume":"40","author":"Lin","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Chen, Y., Wang, Q., Liu, J., Guo, X., Gu, Q., Ding, P., Zhang, H., and Mei, H. (2024). Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1413944"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kontou, A., Kourti, M., Iosifidis, E., Sarafidis, K., and Roilides, E. (2023). Use of newer and repurposed antibiotics against Gram-negative bacteria in neonates. Antibiotics, 12.","DOI":"10.20944\/preprints202305.0017.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13199","DOI":"10.1111\/tid.13199","article-title":"Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study","volume":"22","author":"Chen","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"300060518760435","DOI":"10.1177\/0300060518760435","article-title":"Preliminary experience of tigecycline treatment in critically ill children with ventilator-associated pneumonia","volume":"48","author":"Lin","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.eimc.2019.12.018","article-title":"Tigecycline therapy in pediatric patients with multidrug resistant bacteremia","volume":"38","author":"Gulhan","year":"2020","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.14744\/SEMB.2026.96606","article-title":"Ventilator-Associated Pneumonia in Newborns: Distribution of Causative Agents and Antibiogram","volume":"60","author":"Okay","year":"2026","journal-title":"Med. Bull. Sisli Etfal Hosp."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","article-title":"Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis","volume":"47","author":"Ni","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Poggi, C., and Dani, C. (2023). New Antimicrobials for the Treatment of Neonatal Sepsis Caused by Multi-Drug-Resistant Bacteria: A Systematic Review. Antibiotics, 12.","DOI":"10.3390\/antibiotics12060956"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s15010-024-02404-9","article-title":"Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol","volume":"53","author":"Trauth","year":"2025","journal-title":"Infection"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:50:32Z","timestamp":1788875432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091502"],"URL":"https:\/\/doi.org\/10.3390\/life16091502","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}